Cedars-Sinai Medical Center

Context Therapeutics initiates three research collaborations

Thursday, August 17, 2017

Context Therapeutics, a biotechnology company dedicated to creating new medicines for cancer, fibrosis and neurodegenerative disease, has entered into agreements with three research partners. The company will collaborate with experts in the field of Sigma1 protein and its role in disease biology at the Cedars-Sinai Medical Center, Fred Hutchinson Cancer Research Center and Synergie Lyon Cancer. Context will work with investigators at these institutions to determine the role of Sigma1 in certain animal disease models and to evaluate the activity of its proprietary Sigma1 inhibitors in biopsy explant models, animal models, and human cellular systems.

[Read More]

NIH funds additional medical centers for precision medicine research program

Monday, October 17, 2016

The NIH has announced awards to add four regional medical center groups to the national network of healthcare provider organizations (HPOs) that will implement the Precision Medicine Initiative (PMI) Cohort Program. Combined, the new HPOs will receive initial funds of $5.5 million to begin recruitment and build infrastructure. As efforts advance, the centers may receive first-year funds up to a total of $16 million. The four HPOs join awardees announced earlier this year, to enroll interested individuals, gather participants’ health information and biospecimens and provide input on developing plans for the program.

[Read More]

Synthetic Biologics fills irritable bowel syndrome Clinical Advisory Board

Thursday, October 16, 2014

Synthetic Biologics, a biotechnology company developing novel anti-infective biologics and drugs targeting specific pathogens that cause serious infections and diseases, has expanded its Clinical Advisory Board (CAB) created to support development of SYN-010, the company’s statin-class candidate intended to reduce the impact of methane producing organisms on constipation-predominant irritable bowel syndrome (C-IBS).

[Read More]